BASKING RIDGE, N.J. and JINAN, China, April 23, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, and Qilu Pharmaceutical Co., Ltd. (“Qilu”), one of the leading vertically integrated pharmaceutical companies in China that develops,... Read More

BASKING RIDGE, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the U.S. Food and Drug Administration (the “FDA”) has granted Orphan Drug Designation (“ODD”) to LSTA1, the Company’s lead product... Read More

BASKING RIDGE, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, will participate in the following events in April: LD Micro... Read More

BASKING RIDGE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the U.S. Food and Drug Administration (the “FDA”) has granted Rare Pediatric Disease Designation (“RPDD”) to LSTA1, the Company’s lead... Read More

Phase 2b ASCEND trial fully enrolled and on track for top-line data in fourth quarter of 2024 Company affirms projection of operational funds into early 2026 Conference call scheduled for today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the... Read More

BASKING RIDGE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for twelve months ended December 31, 2023, on Thursday, February 29, 2024, after the close of... Read More

BASKING RIDGE, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata, will present at the BIO CEO & Investor Conference being held on... Read More

BASKING RIDGE, NJ, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata, will deliver a company presentation at the upcoming Sequire Investor... Read More

BASKING RIDGE, N.J., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced treatment of the first patient in a Phase 2a trial evaluating LSTA1 in patients with newly diagnosed glioblastoma multiforme (“GBM”). The trial... Read More

BASKING RIDGE, N.J., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced the publication of a case report detailing a complete response in a patient with metastatic gastroesophageal adenocarcinoma patient treated with... Read More

Enrollment completed approximately six months earlier than originally projected Top-line placebo-controlled, blinded, randomized data now expected in the fourth quarter of 2024 BASKING RIDGE, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other... Read More

BASKING RIDGE, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, will present at NobleCon19, Noble Capital Markets’ Nineteenth Annual... Read More

BASKING RIDGE, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, will present at the following conferences in November: LSX Inv€$tival... Read More

Significant clinical progress achieved in studies evaluating LSTA1 including first patients treated in BOLSTER (3 solid tumor basket trial) and continued rapid enrollment in ASCEND Orphan drug designations granted for LSTA1 in malignant glioma (U.S.) and pancreatic cancer (EU) Company to host conference call Thursday, November 2 at 4:30 p.m. Eastern time BASKING RIDGE, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Lisata... Read More

BASKING RIDGE, N.J., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for third quarter ended September 30, 2023, on Thursday, November 2, 2023, after the close of... Read More

BASKING RIDGE, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced treatment of the first patient in the cholangiocarcinoma cohort of the BOLSTER Trial by Dr. Ian Hu, a principal investigator of the study, at... Read More

BASKING RIDGE, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the European Medicines Agency (“EMA”) Committee for Orphan Medicinal Products has granted orphan drug designation to LSTA1, the Company’s... Read More

BASKING RIDGE, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, will present at two upcoming conferences in October. Details of the... Read More

BASKING RIDGE, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, announces that Gregory Berkin, Chief Information Officer at Lisata, will participate at InfoSec World 2023 being held September 25-27, 2023, in Lake Buena... Read More

Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 in combination with standards of care versus standards of care alone in subjects with advanced solid tumors including cholangiocarcinoma, head and neck squamous cell carcinoma, or esophageal squamous cell carcinoma First patient treated in the head and neck squamous cell carcinoma cohort BASKING RIDGE, N.J., Sept. 12, 2023 (GLOBE... Read More

BASKING RIDGE, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced a positive outcome of the prespecified interim futility analysis for the ASCEND trial, a Phase 2b study evaluating LSTA1, Lisata’s lead... Read More

BASKING RIDGE, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, PhD, Chief Executive Officer of Lisata, will present at two upcoming conferences in September. Details of the events are... Read More

SAN DIEGO , Aug. 15, 2023 /PRNewswire/ -- Impilo Therapeutics, Inc. ("Impilo"), a privately held drug discovery and development company, today announced that it has launched with the mission to enable nucleic acid-based medicines to effectively treat solid tumor cancers. The Company's technology is derived from an agreement with Lisata Therapeutics , Inc. (NASDAQ: LSTA) ("Lisata") for the targeted delivery of nucleic... Read More

Cash runway projected into first quarter 2026 based on capital conservation measures implemented without impact to clinical development pipeline Technology transfer agreement executed for Company’s tumor penetrating nanocomplex (TPN) platform Company to host conference call Tuesday, August 15 at 8:30 a.m. Eastern time BASKING RIDGE, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or... Read More

BASKING RIDGE, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to LSTA1, the Company’s lead product candidate, for the... Read More

BASKING RIDGE, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, announced today that it will report its financial results for the second quarter ended June 30, 2023, on Monday, August 14, 2023, after market trading and will... Read More

BASKING RIDGE, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that Erkki Ruoslahti, M.D., Ph.D., has decided to retire from its Board of Directors effective today, July 11, 2023. Dr. Ruoslahti will remain... Read More

BASKING RIDGE, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, announces its participation in the upcoming GCFF Innovation & Healthcare virtual conference on June 15, 2023. David J. Mazzo, PhD, Chief Executive Officer of... Read More

Target enrollment increased to 155 subjects with the addition of a cohort testing a second dose of LSTA1 Results to be used to explore possible conditional approvals globally Futility analysis results expected in the third quarter of 2023 BASKING RIDGE, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative... Read More

Conference call scheduled for today at 4:30 p.m. Eastern time BASKING RIDGE, N. J., May 09, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provides a business update and reports financial results for the three months ended March 31,... Read More

BASKING RIDGE, N.J., May 02, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the three months ended March 31, 2023, on Tuesday, May 9, 2023, after the close of trading... Read More

BASKING RIDGE, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, PhD, Chief Executive Officer of Lisata, will present at three upcoming conferences. Details of the events are as follows:... Read More

BASKING RIDGE, N.J., April 20, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that it has received $2.2 million in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer... Read More

BASKING RIDGE, NJ, April 19, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, announces its participation in the upcoming Sequire Investor Summit to be held April 24-26, 2023, at La Concha Resort in San Juan, Puerto Rico. David J. Mazzo,... Read More

The iLSTA Trial is the first study combining LSTA1 with standard-of-care chemotherapy and immunotherapy WARPNINE to provide funding and local trial management BASKING RIDGE, N.J. and SUBIACO, Australia, April 18, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and... Read More

BASKING RIDGE, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provides a business update and reports financial results for the three and twelve months ended December 31, 2022. “Last year (2022) was a year of major... Read More

BASKING RIDGE, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the three and twelve months ended December 31, 2022, on Thursday, March 30, 2023, after... Read More

BASKING RIDGE, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that management will present at two upcoming conferences. Details of the events are as follows: 2023 BIO CEO & Investor Conference February 6-9,... Read More

Post-merger profile describes rich clinical development pipeline backed by solid financial situation Qilu Pharmaceutical Phase 1b/2 study of LSTA1 in China ongoing; Preliminary data expected in the second half of 2023 Phase 2b study of LSTA1 in Australia/New Zealand (ASCEND) and LSTA1 Phase 1b/2 study in the U.S. (CENDIFOX) remain on track to complete enrollment in late 2023/early 2024; Data expected in 2024 Company expects... Read More

Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that management will participate in the following events: • RNA at the Bench and Bedside III (November 8-10, 2022) Location: Rosanne M. Crooke, PhD. Conference Center, Carlsbad, CA David Slack,... Read More

Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the three and nine months ended September 30, 2022, on Thursday, November 10, 2022, at 4:30 p.m. (ET). The Company is utilizing a new conference... Read More

Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that management will participate in the following events: RNA USA Leaders Congress 2022 (October 18-19, 2022) Location: The Colonnade Hotel, Boston, MA Session: Closing Keynote Panel: Moving... Read More

Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that Erkki Ruoslahti, M.D., Ph.D., the scientific founder of the Company’s CendR Platform™ technology and a member of the Company’s board of directors, was a recipient of the 2022 Albert Lasker... Read More